It looks like the CHMP, Europe's version of the FDA advisory committee, didn't want the month to end without two big positive opinions, giving investors a nice little present heading into the weekend. Celgene's (NASDAQ:CELG) relapsed and refractory multiple myeloma drug pomalidomide, and Aegerion's (NASDAQ:AEGR) HoFH drug Juxtapid, are now likely to be approved in the EU.
In this video, health-care analyst David Williamson discusses what these events mean for investors in Aegerion and Celgene, along with their competitors.
The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.